# COMBINED MODALITIES:  RADIOTHERAPY AND CHEMOTHERAPY

> **NIH NIH R01** · STANFORD UNIVERSITY · 1987 · $238,214

## Abstract

The longterm objectives of this radiobiological study are centered upon
finding commbinations of radiation with cytotoxic drugs whose effects are
superior to those of the constituent modalities alone or of their algebraic
sums.  The 5 specific aims are:  to investigate the generality of the
supraadditive effect produced when cis-Pt is added to fractionated
radiation (5 daily doses); to investigate the mechanism of this
supra-additive response; to investigate whether supra-additive responses
occur also in important normal tissues and thus to derive therapeutic gain
factors; to investigate whether tumor response is improved using cytotoxic
drugs (notably but not exclusively cis-Pt) combined with fractionated
radiation schedules other than 5 daily doses; to determine whether
supra-additivity is related to the productive recruitment of non-cycling
tumor cells (RIF-1 and EMT6 tumors); and if this is the case, to determine
the optimum times for treatment with different modalities.  All experiments
will be done in mice (C3H/Km or BALB/c/Ka) either on syngeneic tumors
(RIF-1, EMT6, KHT, or SCC VII/St) or on normal tissues.  Tumor response
will assessed by regrowth delay, TCD50, or in vivo/in vitro excision
assay.  Q cell recruitment will be studied by the labeled microcolony
method using SACCAS to analyze autoradiographs.  Normal tissues and
endpoints include spinal cord/myelitis, lung/LD50/160 days, kidney/LD50 2.5
mos. after unilateral nephrectomy, duodenum and colon/crypt survival, and
acute macroscopically visible response of the skin.  The results of this
project should be applicable to human cancer therapy.  Disciplines most
directly involved:  radiobiology, radiation therapy and medical oncology.

## Key facts

- **NIH application ID:** 3172258
- **Project number:** 5R01CA034544-05
- **Recipient organization:** STANFORD UNIVERSITY
- **SAM.gov UEI:** HJD6G4D6TJY5
- **Principal Investigator:** ROBERT FRIEND KALLMAN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $238,214
- **Award type:** 5
- **Project period:** 1983-05-01 → 1988-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3172258

## Citation

> US National Institutes of Health, RePORTER application 3172258, COMBINED MODALITIES:  RADIOTHERAPY AND CHEMOTHERAPY (5R01CA034544-05). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3172258. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*